REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital

REGENXBIO (NASDAQ:RGNX - Get Free Report)'s stock had its "buy" rating restated by Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $52.00 price objective on the biotechnology company's stock. Chardan Capital's price target points to a potential upside of 375.75% from the company's previous close.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "sell" rating in a research note on Sunday. Royal Bank Of Canada lifted their target price on REGENXBIO from $17.00 to $19.00 and gave the company an "outperform" rating in a research report on Friday, November 7th. Barclays lowered their price target on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of REGENXBIO in a report on Wednesday, October 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of REGENXBIO in a report on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and an average target price of $28.63.

Get Our Latest Stock Report on REGENXBIO

REGENXBIO Trading Down 2.8%

Shares of RGNX stock opened at $10.93 on Thursday. The firm has a fifty day simple moving average of $11.07 and a two-hundred day simple moving average of $9.61. REGENXBIO has a 12 month low of $5.03 and a 12 month high of $13.93. The firm has a market capitalization of $553.28 million, a PE ratio of -3.15 and a beta of 1.23.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.38) by $0.18. The firm had revenue of $29.73 million during the quarter, compared to analysts' expectations of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. On average, equities analysts predict that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. The trade was a 8.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 36,169 shares of company stock worth $416,598. Company insiders own 12.79% of the company's stock.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in REGENXBIO by 4.8% in the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company's stock worth $38,959,000 after acquiring an additional 185,223 shares during the period. Vanguard Group Inc. raised its holdings in shares of REGENXBIO by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock worth $24,832,000 after purchasing an additional 487,036 shares during the period. Geode Capital Management LLC lifted its stake in REGENXBIO by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company's stock valued at $9,267,000 after purchasing an additional 21,575 shares during the last quarter. Integral Health Asset Management LLC grew its holdings in REGENXBIO by 57.1% during the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $10,615,000 after purchasing an additional 400,000 shares during the period. Finally, AQR Capital Management LLC increased its position in REGENXBIO by 49.9% in the second quarter. AQR Capital Management LLC now owns 930,196 shares of the biotechnology company's stock worth $7,637,000 after buying an additional 309,601 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Articles

• Five stocks we like better than REGENXBIO
• Stock Splits, Do They Really Impact Investors?
• Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
• 10 Best Airline Stocks to Buy
• Applied Materials: Up 40% in 2025 With Room to Run Long-Term
• Canadian Penny Stocks: Can They Make You Rich?
• onsemi Places a $6 Billion Bet on Its Own Stock

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in REGENXBIO Right Now?

Before you consider REGENXBIO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.

While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here